Drug intelligence / Profile preview

autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (Northwestern University)

Development stage
Unknown
Lead developer
Northwestern University
Modality
Cell Therapies
Administration
Intravenous
01

Overview

Autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) are an adoptive cellular immunotherapy developed by **Northwestern University**. This therapy involves the ex vivo expansion of a patient's own T cells that have been specifically sensitized to recognize and eliminate cells infected with the **Epstein-Barr virus (EBV)**. It is primarily investigated for the treatment and prevention of EBV-induced **post-transplant lymphoproliferative disorder (PTLD)** in recipients of solid organ or hematopoietic stem cell transplants. By restoring EBV-specific immunity, these CTLs target EBV-positive B-cell proliferations, providing a targeted alternative to traditional chemotherapy or reduction of immunosuppression.

Other names
autologous EBV-CTLsautologous EBV-specific T cellsautologous EBV-specific cytotoxic T lymphocytes
02

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (Northwestern University).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (Northwestern University).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call